Increased expression of 5-lipoxygenase is common in clear cell renal cell carcinoma

Histology and Histopathology

Volumn 22, Issue 10-12, 2007, Pages 1109-1118

  Faronato, M ^a   Muzzonigro, G ^a   Milanese, G ^a   Menna, C ^a,b   Bonfigli, A R ^b   Catalano, A ^a,b   Procopio, A ^a,b  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INRCA   (Italy)

Author keywords

5 lipoxygenase; Eiocasanoids; Renal cell carcinoma; Tumor progression

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; LEUKOTRIENE; MESSENGER RNA; SMALL INTERFERING RNA; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN; CARRIER PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN A; VBP1 PROTEIN, HUMAN; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CATALYSIS; CELL CULTURE; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENDER; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR VOLUME; UPREGULATION; ADENOCARCINOMA; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; KIDNEY TUMOR; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; ARACHIDONATE 5-LIPOXYGENASE; BASE SEQUENCE; CARCINOMA, RENAL CELL; CARRIER PROTEINS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34547573355     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Avis I.M., Jett M., Boyle T., Vos M.D., Moody T., Treston A.M., Martinez A. and Mulshine J.L. (1996). Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signalling. J. Clin. Invest. 97, 806-813.
2. Avnet S., Cenni E., Granchi D., Perut F., Amato I., Battistelli L., Brandi M.L., Giunti A. and Baldini N. (2004). Isolation and characterization of a new cell line from a renal carcinoma bone metastasis. Anticancer Res. 24, 1705-1711.
3. Breton J., Woolf D., Young P. and Chabot-Fletcher M. (1996). Human keratinocytes lack the components to produce leukotriene B4. J. Invest. Dermatol. 106, 162-167.
4. Catalano A. and Procopio A. (2005). New aspects on the role of lipoxygenases in cancer progression. Histol. Histopathol. 20, 969-975.
5. Catalano A., Rodilossi S., Caprari P., Coppola V. and Procopio A. (2005). 5-Lipoxygenase regulates senescence-like growth arrest by promoting ROS-dependent p53 activation. EMBO J. 24, 170-179.
6. Damtew B. and Spagnuolo P.J. (1997). Tumour cell-endothelial cell interactions: evidence for roles for lipoxygenase products of arachidonic acid in metastasis. Prostagland. Leuko. Ess. Fatty Acids 56, 295-300.
7. Fleming I.D., Cooper J.S., Henson D.E., Hutter R.V., Kennedy B.J., Murphy G.P., O'Sullivan B., Sobin L.H. and Yarbrau J.W. (1997). AJCC Cancer Staging Manual. 5th ed. Lippincott-Raven. Philadelphia. pp 231-232.
8. Hashimoto Y., Kondo Y., Kimura G., Matsuzawa I., Sato S., Ishizaki M., Imura N., Akimoto M. and Hara S. (2004). Cyclooxygenase-2 expression and relationship to tumour progression in human renal cell carcinoma. Histopathology 44, 353-359.
9. Hennig R., Grippo P., Ding X.Z., Rao S.M., Buchler M.W., Friess H., Talamonti M.S., Bell R.H. and Adrian T.E. (2005). 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. Cancer Res. 65, 6011-6016.
10. Hong S.H., Avis I., Vos M.D., Martinez A., Treston A.M. and Mulshine J.L. (1999). Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res. 59, 2223-2228.
11. Jacobsen J., Rasmuson T., Grankvist K. and Ljungberg B. (2000). Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J. Urol. 163, 343-347.
12. Jiang W.G., Douglas-Jones A.G. and Mansel R.E. (2006). Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer. Prostaglandins Leukot. Essent. Fatty Acids 74, 125-134.
13. Lewis R.A., Austen K.F. and Soberman R.J. (1990). Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N. Engl. J. Med. 323, 645-655.
14. Matsuyama M., Yoshimura R., Mitsuhashi M., Hase T., Tsuchida K., Takemoto Y., Kawahito Y., Sano H. and Nakatani T. (2004a). Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors. Int. J. Oncol. 24, 821-827.
15. Matsuyama M., Yoshimura R., Tsuchida K., Takemoto Y., Segawa Y., Shinnka T., Kawahito Y., Sano H. and Nakatani T. (2004b). Lipoxygenase inhibitors prevent urological cancer cell growth. Int. J. Mol. Med. 13, 665-668.
16. Matsuyama M., Yoshimura R., Mitsuhashi M., Tsuchida K., Takemoto Y., Kawahito Y., Sano H. and Nakatani T. (2005). 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway. Oncol. Rep. 14, 73-79.
17. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R. and Ratcliffe P.J. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygendependent proteolysis. Nature 399, 271-275.
18. Minardi D., Lucarini G., Mazzucchelli R., Milanese G., Natali D., Galosi A.B., Montironi R., Biagini G. and Muzzonigro G. (2005). Prognostic role of Fuhrman grade and vascular endothelial growth factor in pT1a clear cell carcinoma in partial nephrectomy specimens. J. Urol. 174, 1208-1212.
19. Na X., Wu G., Ryan C.K., Schoen S.R., di'Santagnese P.A. and Messing E.M. (2003). Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J. Urol. 170, 588-592.
20. Natarajan R. and Reddy M.A. (2003). HETEs/EETs in renal glomerular and epithelial cell functions. Curr. Opin. Pharmacol. 3, 198-203.
21. Nie D., Krishnamoorthy S., Jin R., Tang K., Chen Y., Qiao Y., Zacharek A., Guo Y., Milanini J., Pages G. and Honn K.V. (2006). Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells. J. Biol. Chem. 281, 18601-18609.
22. Öhd J.F., Nielsen C.K., Campbell J., Landberg G., Lööfberg H. and Sjöölander A. (2003). Expression of the leukotriene D4 receptor CysLT1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology 124, 57-70.
23. Reich R. and Martin G.R. (1996). Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells. Prostaglandins 51, 1-17.
24. Reuter V.E. and Presti J.C. (2000). Contemporary approach to the classification of renal epithelial tumors. Semin. Oncol. 27, 124-137.
25. Romano M., Catalano A., Nutini M., D'Urbano E., Crescenzi C., Claria J., Libner R., Davi G. and Procopio A. (2001). 5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. FASEB J. 15, 2326-2336.
26. Schraml P., Struckmann K., Hatz F., Sonnet S., Kully C., Gasser T., SauterG., Mihatsch M.J. and Moch H. (2002). VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J. Pathol. 196, 186-193.
27. Shureiqi I., Wu Y., Chen D., Yang X.L., Guan B., Morris J.S., Yang P., Newman R.A. and Lippman S.M. (2005). The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. Cancer Res. 65, 11486-11492.
28. Soberman R.J. and Christmas P. (2003). The organization and consequences of eicosanoid signalling. J. Clin. Invest. 111, 1107-1113.
29. Turner K.J., Moore J.W., Jones A., Taylor C.F., Cuthbert-Heavens D., Han C., Leek R.D., Gatter K.C., Maxwell P.H., Ratcliffe P.J., Cranston D. and Harris A.L. (2002). Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res. 62, 2957-2961.
30. Wenger F.A., Kilian M., Bisevac M., Khodadayan C., von Seebach M., Schimke I., Guski H. and Muller J.M. (2002). Effects of Celebrex and Zyflo on liver metastasis and lipidperoxidation in pancreatic cancer in Syrian hamsters. Clin. Exp. Metastasis 19, 681-687.